Keros Therapeutics (KROS) Return on Equity (2019 - 2025)

Keros Therapeutics has reported Return on Equity for 7 years, with the latest figure at 0.0% in Q4 2025.

• For the quarter ending Q4 2025, Return on Equity rose 1.0% year-over-year to 0.0%; the trailing twelve-month figure through Dec 2025 stood at 0.0% (up 1.0% YoY), and the FY2025 full-year result was 0.0%, up 1.0% from the prior year.
• Return on Equity for Q4 2025 stood at 0.0%, up from 0.0% in the prior quarter.
• The five-year high for Return on Equity was 0.0% in Q4 2025, with the low at 0.01% in Q4 2023.
• Historically, Return on Equity has averaged 0.0% across 5 years, with a median of 0.0% in 2022.
• Annual changes were most pronounced in 2021 — Return on Equity slipped 1 bps — and 2025, when it gained 1 bps.
• Keros Therapeutics' Return on Equity stood at 0.0% in 2021, then sank by 59 bps to 0.0% in 2022, then slumped by 34 bps to 0.01% in 2023, then surged by 37 bps to 0.0% in 2024, then jumped by 151 bps to 0.0% in 2025.
• The last three Return on Equity figures came in at 0.0% (Q4 2025), 0.0% (Q3 2025), and 0.0% (Q2 2025), per Business Quant data.